Related Experiment Video
Updated: May 2, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro
Amir S Youssef1, Henry P Parkman, Swati Nagar
1Department of Pharmaceutical Sciences and.
Abstract:
Domperidone (prokinetic agent) is frequently co-administered with pioglitazone (anitidiabetic) or ondansetron (antiemetic) in gastroparesis management. These drugs are metabolized via cytochome P-450 (CYP) 3A4, raising the possibility of interaction and adverse reactions. The concentration-dependent inhibitory effect of pioglitazone and ondansetron on domperidone hydroxylation was monitored in pooled human liver microsomes (HLM). Pioglitazone was further assessed as a mechanism-based inhibitor. Microsomal binding was evaluated in our assessment. In HLM, Vmax/Km estimates for monohydroxy domperidone formation decreased in presence of pioglitazone. Diagnostic plots indicated that pioglitazone inhibited domperidone in a partial mixed-type manner. The in vitro Ki was 1.52 µM. Predicted in vivo AUCi/AUC ratio was 1.98. Pioglitazone also exerted time-dependent inhibition on the metabolism of domperidone and the average remaining enzymatic activity decreased significantly upon preincubation with pioglitazone over 0-40 min. Diagnostic plots showed no inhibitory effect of ondansetron on domperidone hydroxylation. 6. In conclusion, pioglitazone inhibited domperidone metabolism in vitro through different complex mechanisms. Our in vitro data predict that the co-administration of these drugs can potentially trigger an in vivo drug-drug interaction.
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Oral Hypoglycemic Agents: Biguanides and Glitazones
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Dipeptidyl Peptidase 4 Inhibitors
Pharmacokinetics: Drug–Drug Interactions
Drug toxicity: Drug–Drug Interaction

